Cagrilintide-semaglutide plus basal insulin lowered A1C and weight in adults with type 2 diabetes 24th September 20265th July 2026 by Living Diabetes Editorial A Lancet phase 3a trial found cagrilintide-semaglutide added to basal insulin lowered A1C and weight in adults with type 2 diabetes.
